Overview
An extra tube of blood for research will be collected from consented subjects prior to the initiation of anti-PD-1/L1 based immunotherapy, either single agent or in combination with chemotherapy. The blood will be coded, processed and sent for analysis. Results of analysis will be correlated with clinical data to see whether serum proteomics can be a good therapeutic predictor for future studies and treatments of NSCLC.
Principal investigator
Eligibility criteria
Inclusion Criteria:
- Non Small Cell Lung Cancer (NSCLC) patients who were previously untreated receiving anti-PD1 or anti-PD-L1 therapies, either single agent or in combination with chemotherapy.
- NSCLC patients who were treated with one previous line of therapy (not containing IO) and now receiving anti-PD1 or anti-PD-L1 therapies, either single agent or in combination with chemotherapy.
Exclusion Criteria:
- Patients not capable of making medical decisions
- Any patients who do not meet the inclusion criteria
For Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.